Research-based PAM50 signature and long-term breast cancer survival.
Minya PuKaren MesserSherri R DaviesTammi L VickeryEmily PittmanBarbara A ParkerMatthew J EllisShirley W FlattCatherine R MarinacSandahl H NelsonElaine R MardisJohn P PierceLoki NatarajanPublished in: Breast cancer research and treatment (2019)
PAM50 intrinsic subtypes were independently prognostic for long-term breast cancer survival, irrespective of menopausal status. Addition of hypoxia signatures improved risk prediction. If replicated, incorporating the 13-gene hypoxia signature into the existing PAM50 risk assessment tool, may refine risk stratification and further clarify treatment for breast cancer.